Erlotinib u nemocných s nemalobuněčným karcinomem plic (NSCLC) účinný u všech podskupin nemocných i v České republice

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Erlotinib in patients with non-small cell lung cancer (NSCLC): Efficacy in all subgroups of patients even in the Czech Republic
Authors

SKŘIČKOVÁ Jana PEŠEK M. ZATLOUKAL P.

Year of publication 2010
Type Article in Proceedings
Conference Edukační sborník
MU Faculty or unit

Faculty of Medicine

Citation
Field Pneumology
Keywords Erlotinib; NSCLC; Czech Republic
Description A multi-centre study confirms efficacy of Erlotinib in treatment of NSCLC in all subgroups of patients with non-small cell lung cancer (NSCLC). Efficacy in all patient subgroups was confirmed even in the Czech Republic
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.